Table 1. Clinicopathologic... | Rockefeller University Press

Table 1.

Clinicopathologic characteristics of 57 specimens from 50 patients

Characteristic	Untreated	Sensitive	Resistant
Number of patients	25	18	9^a
Number of specimens	25	23	9
Median age (range)	65 (38-85)	58 (43-81)	53 (39-66)
Female	13	4	3
Male	12	14	6
Primary	25	9	2
Metastatic	0	14	6
Local recurrence	0	0	1
Primary location
Stomach	23	7	4
Small intestine	1	12	4
Other	1	4	1
Tyrosine kinase inhibitor
Imatinib	Not applicable	23	9
Sunitinib	Not applicable	0	5
Other	Not applicable	0	2
Median treatment duration (months)	Not applicable	6 (3-84)	84 (36-132)^b
Mutational status
KIT exon 9	0	2	1
KIT exon 11	6	9^c	8^d
KIT exon 13	0	1	0
PDGFRA	2	0	0
WT	2	0	0
Unavailable	15	6	0

Characteristic	Untreated	Sensitive	Resistant
Number of patients	25	18	9^a
Number of specimens	25	23	9
Median age (range)	65 (38-85)	58 (43-81)	53 (39-66)
Female	13	4	3
Male	12	14	6
Primary	25	9	2
Metastatic	0	14	6
Local recurrence	0	0	1
Primary location
Stomach	23	7	4
Small intestine	1	12	4
Other	1	4	1
Tyrosine kinase inhibitor
Imatinib	Not applicable	23	9
Sunitinib	Not applicable	0	5
Other	Not applicable	0	2
Median treatment duration (months)	Not applicable	6 (3-84)	84 (36-132)^b
Mutational status
KIT exon 9	0	2	1
KIT exon 11	6	9^c	8^d
KIT exon 13	0	1	0
PDGFRA	2	0	0
WT	2	0	0
Unavailable	15	6	0

Two patients also had sensitive tumors.

Shows duration of any treatment.

One patient had a secondary KIT exon 17 mutation but was still sensitive by clinical criteria.

Two patients had secondary KIT exon 13 mutations and 1 had a secondary KIT exon 17 mutation.